BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
36 hedge funds and large institutions have $8.69M invested in BRAINSTORM CELL THERAPUTC in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0.02% more ownership
Funds ownership: 0.76% → 0.79% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $9.04M → $8.69M (-$351K)
3% less funds holding
Funds holding: 37 → 36 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
50% less call options, than puts
Call options by funds: $7K | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$341K |
| 2 |
Renaissance Technologies
New York
|
+$159K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$94.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$35.7K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$33.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$395K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$47K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$31.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$25K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
-$23K |
BCLI Hedge Fund Activity: Q4 2018 in Review
36 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2018, worth a combined $8.69M — down 3.9% from $9.04M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BCLI and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 8 added.
The largest buyer was Sabby Management, adding an estimated $341K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $395K sold.
- 36 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2018, down from 37 in Q3 2018.
- Funds reported $8.69M of BRAINSTORM CELL THERAPUTC stock for Q4 2018, down 3.9% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2018 and 5 closed out, a net change of -1 holder.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2018 was Sabby Management, an estimated $341K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2018 was JP Morgan Chase, an estimated $395K sold.
Based on aggregated 13F filings for Q4 2018.